{"product_id":"expanding-early-detection-of-prostate-cancer-what-men-at-high-risk-need-to-know","title":"Expanding Early Detection of Prostate Cancer: What Men at High Risk Need to Know","description":"This patient-friendly article translates a scientific paper into clear, actionable guidance for men concerned about prostate cancer risk.\n\n\u003cp\u003eProstate cancer remains one of the most challenging cancers to screen for, with current approaches often missing men at highest genetic risk while over-treating those at low risk. New research reveals that 57% of prostate cancer risk comes from inherited genetic factors, yet structured screening pathways for high-risk men remain largely unavailable outside of research studies. This article from European Urology Oncology reviews the evidence on genetic risk, family history, and ancestry, and issues a clear call to action: men at elevated risk need earlier, more structured screening — and the tools to make that happen are finally within reach.\u003c\/p\u003e\n\n\u003ch1\u003eExpanding Early Detection of Prostate Cancer: What Men at High Risk Need to Know\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why Prostate Cancer Screening Needs to Change\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#high-risk\"\u003eWho Is at High Risk for Prostate Cancer?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#care-gaps\"\u003eCurrent Gaps in Prostate Cancer Care\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations: How Early Detection Should Be Expanded\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#screening-pathways\"\u003eWhat a Structured Screening Pathway Looks Like\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#conclusions\"\u003eConclusions: A Coordinated Call to Action\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eWhat This Study Could Not Answer\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#for-patients\"\u003eWhat This Means for You: Practical Steps\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e57% of prostate cancer risk comes from inherited genetic factors, making genetic testing and risk-stratified screening urgent.\u003c\/li\u003e\n\u003cli\u003e37% of dangerous genetic mutations occurred in men with no family history, so family history alone misses many carriers.\u003c\/li\u003e\n\u003cli\u003eMen of African ancestry have a 2.18-fold higher genetic risk; Ashkenazi Jewish men have highest germline variant prevalence.\u003c\/li\u003e\n\u003cli\u003eHigh-risk screening should start at age 40 for PGV carriers or 45 with strong family history, using annual PSA and mpMRI.\u003c\/li\u003e\n\u003cli\u003eA negative genetic test does not cancel a strong family history; family history remains an independent risk factor.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why Prostate Cancer Screening Needs to Change\u003c\/h2\u003e\n\n\u003cp\u003eProstate cancer (PCa) is a major global health challenge, and the way we currently screen for it is not working well for everyone. Widespread \u003cstrong\u003eopportunistic screening\u003c\/strong\u003e — meaning PSA blood tests done without a formal, organized program — has led to overdiagnosis and overtreatment, especially in men over 70 years old. This creates unnecessary health-care costs and burdens patients with treatments they may not need, while only providing a limited improvement in cancer-specific survival for the general population.\u003c\/p\u003e\n\n\u003cp\u003eThe problem is especially serious for men at elevated risk. Current screening strategies fail to adequately identify individuals with \u003cstrong\u003eheritable risk\u003c\/strong\u003e — risk passed down through families and genes. The authors of this paper argue that a structured, risk-adapted approach is essential for two main reasons:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eTo minimize overdiagnosis and overtreatment in men with low prostate cancer risk\u003c\/li\u003e\n  \u003cli\u003eTo improve early detection and survival in men with high prostate cancer risk\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eThis is not a new idea in cancer care. Risk-adapted strategies have already been successfully implemented for breast and ovarian cancer, where genetic testing and tailored screening are standard practice. Prostate cancer has lagged behind, despite clear guideline recommendations. The authors note that \u003cstrong\u003e57% of prostate cancer risk is attributable to inherited genetic factors\u003c\/strong\u003e, making the case for genetic testing and risk-stratified screening all the more urgent.\u003c\/p\u003e\n\n\u003ch2 id=\"high-risk\"\u003eWho Is at High Risk for Prostate Cancer?\u003c\/h2\u003e\n\n\u003cp\u003eProstate cancer risk is \u003cstrong\u003emultifactorial\u003c\/strong\u003e, meaning many factors combine to determine a man's overall risk. The primary risk factors well established in the medical literature include age, family history, hereditary syndromes, and ancestry. Each contributes differently, and understanding all of them is key to identifying who needs earlier or more intensive screening.\u003c\/p\u003e\n\n\u003ch3\u003eFamily History: The Strongest Clinical Clue\u003c\/h3\u003e\n\u003cp\u003eFamily history is a powerful predictor. It has been linked to a higher risk of \u003cstrong\u003ehigh-grade prostate cancer\u003c\/strong\u003e (more aggressive disease) and earlier onset of the disease. The highest risk is seen in men whose \u003cstrong\u003efirst-degree relatives\u003c\/strong\u003e (father, brother, or son) have been affected by prostate cancer. Interestingly, the risk is inversely related to the age at which the family member was diagnosed — meaning if your father or brother was diagnosed young, your own risk is even higher.\u003c\/p\u003e\n\n\u003cp\u003eOne often-overlooked finding is that a family history of \u003cstrong\u003ebreast, ovarian, or colorectal cancer\u003c\/strong\u003e also raises a man's prostate cancer risk. This is because these cancers share overlapping genetic variants, particularly in \u003cstrong\u003eDNA repair\u003c\/strong\u003e and \u003cstrong\u003emismatch repair\u003c\/strong\u003e pathways — the same genes that, when mutated, can predispose to multiple cancer types.\u003c\/p\u003e\n\n\u003ch3\u003eInherited Genetic Variants (Pathogenic Germline Variants, or PGVs)\u003c\/h3\u003e\n\u003cp\u003eFamilial prostate cancer risk is driven in large part by inherited genetic mutations called \u003cstrong\u003epathogenic germline variants (PGVs)\u003c\/strong\u003e. The key genes involved include DNA repair genes such as \u003cstrong\u003eBRCA1, BRCA2, HOXB13, ATM, CHEK2, PALB2, TP53, RAD51, and NBN\u003c\/strong\u003e, as well as the mismatch repair genes associated with Lynch syndrome: \u003cstrong\u003eMLH1, MSH2, MSH6, PMS2, and EPCAM\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eSome genes carry more weight than others. Mutations in \u003cstrong\u003eBRCA2 and HOXB13\u003c\/strong\u003e are associated with the highest increase in prostate cancer risk, and \u003cstrong\u003eBRCA2\u003c\/strong\u003e mutations are also linked to more aggressive disease. The prevalence of these genetic variants increases with disease severity:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003e4.6%\u003c\/strong\u003e in localized prostate cancer (confined to the prostate)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e11.8%\u003c\/strong\u003e in metastatic disease (spread to other parts of the body)\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003e16.2%\u003c\/strong\u003e in metastatic castration-resistant prostate cancer (the most advanced stage)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eA large study by Nicolosi and colleagues found a PGV rate of \u003cstrong\u003e17.2%\u003c\/strong\u003e among individuals with a history of prostate cancer regardless of disease stage. Broken down by gene, the rates were BRCA2 at \u003cstrong\u003e4.74%\u003c\/strong\u003e, CHEK2 at \u003cstrong\u003e2.88%\u003c\/strong\u003e, ATM at \u003cstrong\u003e2.03%\u003c\/strong\u003e, and BRCA1 at \u003cstrong\u003e1.25%\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eHere is one of the most important findings for patients: \u003cstrong\u003e37% of PGVs occurred in individuals with no family history of prostate cancer at all\u003c\/strong\u003e. This means that if genetic testing were offered only to men with a known family history, more than one-third of men carrying dangerous mutations would be missed.\u003c\/p\u003e\n\n\u003ch3\u003ePolygenic Risk Scores: Many Small Genetic Changes Add Up\u003c\/h3\u003e\n\u003cp\u003eBeyond the high-impact single-gene mutations, there are hundreds of small genetic variations called \u003cstrong\u003esingle-nucleotide polymorphisms (SNPs)\u003c\/strong\u003e. Genome-wide association studies have identified more than \u003cstrong\u003e451 SNPs\u003c\/strong\u003e associated with prostate cancer. When combined, their cumulative effect can be quantified using a \u003cstrong\u003epolygenic risk score (PRS)\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003ePRS has been shown to improve the detection of clinically significant prostate cancer in prospective studies, complementing standard tools like MRI and PSA testing. However, current genetic testing cannot capture all relevant risk variants. Earlier PRS models based on \u003cstrong\u003e269 SNPs captured only 30–40% of familial relative risk\u003c\/strong\u003e. This is why the authors stress that \u003cstrong\u003efamily history must remain a separate risk factor\u003c\/strong\u003e even after genetic testing — a negative genetic test does not erase a strong family history.\u003c\/p\u003e\n\n\u003cp\u003eThe stakes are high. A combination of familial risk, a high PRS, and unfavorable lifestyle factors is associated with a \u003cstrong\u003ethreefold higher risk of death from prostate cancer before the age of 75 years\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch3\u003eAncestry: A Critical but Under-Recognized Factor\u003c\/h3\u003e\n\u003cp\u003eAncestry significantly modifies prostate cancer risk. The statistics are striking:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eMen of \u003cstrong\u003eAfrican ancestry\u003c\/strong\u003e have on average a \u003cstrong\u003e2.18-fold higher\u003c\/strong\u003e genetic risk of prostate cancer (95% CI 2.14–2.22) compared with men of European ancestry.\u003c\/li\u003e\n  \u003cli\u003eMen of \u003cstrong\u003eEast Asian ancestry\u003c\/strong\u003e have a \u003cstrong\u003e0.73-fold lower\u003c\/strong\u003e risk (95% CI 0.71–0.76).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eGermline variant prevalence also varies by ancestry. It is highest in \u003cstrong\u003eAshkenazi Jewish (22.7%)\u003c\/strong\u003e and \u003cstrong\u003eWhite (17.8%)\u003c\/strong\u003e men, and lowest in \u003cstrong\u003eAfrican American (10.1%)\u003c\/strong\u003e and \u003cstrong\u003eHispanic (6.4%)\u003c\/strong\u003e men. However, the picture is complicated: prostate cancer incidence and mortality are actually higher among Black men in the USA, a disparity driven not only by biology but also by \u003cstrong\u003esocial determinants of health\u003c\/strong\u003e, such as health-care availability, access to screening, and other social factors.\u003c\/p\u003e\n\n\u003cp\u003eNon-White populations remain under-represented in research and germline testing guidelines. This leads to a lower diagnostic yield and higher rates of \u003cstrong\u003evariants of uncertain significance\u003c\/strong\u003e — genetic changes that doctors cannot yet confidently classify as harmful or harmless. The authors call for inclusive genomic data and \u003cstrong\u003eancestry-informed strategies\u003c\/strong\u003e for early detection, a point echoed by recent research on rare pathogenic structural variants in African men and aggressive prostate cancer in men of African ancestry.\u003c\/p\u003e\n\n\u003ch2 id=\"care-gaps\"\u003eCurrent Gaps in Prostate Cancer Care\u003c\/h2\u003e\n\n\u003cp\u003eDespite growing evidence about genetic and familial risk, the clinical integration of risk-adapted early detection remains very limited. The contrast with breast and ovarian cancer is stark. For those cancers, risk assessment programs and genetic testing are well established. For prostate cancer, significant gaps persist, and the consequences are measurable.\u003c\/p\u003e\n\n\u003ch3\u003eThe Gender Gap in Genetic Testing\u003c\/h3\u003e\n\u003cp\u003eSeveral studies highlight substantial gender disparities: women with breast or ovarian cancer are far more likely to undergo genetic testing than men with prostate cancer. The same disparity extends to unaffected relatives. Test results are also communicated to male relatives less often within families, likely because the relevance of \u003cstrong\u003efemale family history\u003c\/strong\u003e (such as a mother's breast cancer or a sister's ovarian cancer) for men's prostate cancer risk is underestimated. Men also report difficulty finding tailored information, underscoring the need for male-focused resources.\u003c\/p\u003e\n\n\u003cp\u003eWhy the underutilization? Researchers point to limited awareness among both patients and clinicians, gender-related social roles, and men's generally lower engagement in preventive care. These are not minor issues — they represent \u003cstrong\u003emissed opportunities for cascade testing\u003c\/strong\u003e (testing family members of someone with a known mutation) and potential treatment adaptations.\u003c\/p\u003e\n\n\u003ch3\u003eOpportunistic Screening: Skewed and Inefficient\u003c\/h3\u003e\n\u003cp\u003eEarly detection of prostate cancer remains largely opportunistic in many countries. That means screening happens by chance — when a man happens to see a doctor who orders a PSA test — rather than through a structured program targeting those at highest risk. This leads to a skewed uptake:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eHigher PSA testing rates among \u003cstrong\u003ewealthier, more educated men\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eLower uptake among \u003cstrong\u003eminority groups\u003c\/strong\u003e\n\u003c\/li\u003e\n  \u003cli\u003eOngoing overdiagnosis and overtreatment, especially in men \u003cstrong\u003eover age 70\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eMeanwhile, although guidelines recommend earlier screening for men at high risk of prostate cancer, implementation is mostly confined to research studies. Structured clinical screening pathways and guidance written for patients themselves still need to be developed. There is also \u003cstrong\u003eno consensus on which precise group of PGVs\u003c\/strong\u003e should be universally considered high-risk and included in intensified screening programs. Finally, insurance coverage for genetic testing varies greatly by region, limiting access even for those with explicit family histories.\u003c\/p\u003e\n\n\u003ch3\u003eThe Psychological Side of Genetic Testing\u003c\/h3\u003e\n\u003cp\u003eThe authors also raise an often-overlooked concern: the potential \u003cstrong\u003epsychosocial burden\u003c\/strong\u003e of genetic testing in men at high risk of prostate cancer. The IMPACT study, a prospective study of men with BRCA1\/2 mutations, found \u003cstrong\u003elow and largely stable psychosocial distress levels\u003c\/strong\u003e among carriers over time. But a subgroup of carriers did report heightened distress. These men may benefit from tailored psychological screening and support, but such support structures are currently \u003cstrong\u003enot implemented in regular care\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eGenetic counseling must therefore address each patient's individual situation and take into account the potential psychological burden. This also concerns psycho-oncological health care professionals, who are often the first point of contact for distressed patients but may lack specific training in the clinical issues related to genetic testing.\u003c\/p\u003e\n\n\u003cp\u003eThere are signs of movement. Sweden has launched a pilot screening program for risk-adapted early detection, and Germany has issued funding calls for the development and evaluation of risk-based screening algorithms. Governments are beginning to act — but the authors argue that much more is needed.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations: How Early Detection Should Be Expanded\u003c\/h2\u003e\n\n\u003cp\u003eThe authors lay out a comprehensive set of recommendations spanning risk assessment, genetic testing, screening pathways, and education. Their goal is to create a system that proactively reaches high-risk men rather than waiting for them to stumble into screening.\u003c\/p\u003e\n\n\u003ch3\u003eRisk Assessment, Communication, and Awareness\u003c\/h3\u003e\n\n\u003cp\u003eThe first step is to \u003cstrong\u003edefine standardized criteria for genetic testing eligibility\u003c\/strong\u003e based on family history and hereditary risk — and these criteria must explicitly include men with prostate cancer. Current guidelines partly overlap but also differ in their definitions, which makes it difficult to compare studies linking family history to PGVs. Standardization would improve both clinical care and research.\u003c\/p\u003e\n\n\u003cp\u003eThe authors recommend that \u003cstrong\u003eroutine risk assessment in primary care\u003c\/strong\u003e should include ancestry and family history of prostate cancer, PGVs, and breast, ovarian, and colorectal cancers. To make this workable, they call for validated, easy-to-use tools for primary care doctors to assess familial cancer history and ancestry — analogous to breast cancer tools such as the \u003cstrong\u003eHelix Tool\u003c\/strong\u003e. These tools would help identify known genetic variants in a family and facilitate standardized referral to genetic counseling.\u003c\/p\u003e\n\n\u003cp\u003eFor men with prostate cancer who meet genetic testing criteria (based on family history or metastatic disease), the treating urologist or oncologist should \u003cstrong\u003einitiate referral at diagnosis and before treatment\u003c\/strong\u003e. This timing matters because the results may affect the choice of therapy and trigger cascade testing of family members. Genetic counseling should involve \u003cstrong\u003eshared decision-making\u003c\/strong\u003e and address ethical, legal, and social aspects.\u003c\/p\u003e\n\n\u003ch3\u003eExpanding Cascade Testing\u003c\/h3\u003e\n\u003cp\u003eTo expand cascade testing (testing relatives of mutation carriers), the authors recommend targeted education for both providers and patients. This education should correct misconceptions and highlight the importance of PGVs — especially in \u003cstrong\u003eBRCA1\/2\u003c\/strong\u003e — for male relatives. They also suggest offering \u003cstrong\u003efamily letter templates\u003c\/strong\u003e to PGV carriers to support communication of test results to relatives, along with information on how to access genetic testing. For patients, centralized information materials should be developed in plain, lay language.\u003c\/p\u003e\n\n\u003cp\u003eThe authors acknowledge real-world barriers: the financial burden and the limited availability of trained genetic professionals. But they note that as testing costs continue to decline and resource-sparing models emerge, the value of germline testing is becoming increasingly clear — especially when weighed against the \u003cstrong\u003epotentially substantial costs of treating advanced prostate cancer\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003ch2 id=\"screening-pathways\"\u003eWhat a Structured Screening Pathway Looks Like\u003c\/h2\u003e\n\n\u003cp\u003eImplementation of risk-adapted screening pathways for high-risk men is crucial to balance sensitivity (finding real cancers) against overdiagnosis (finding harmless ones). Importantly, the authors emphasize that \u003cstrong\u003ea negative germline test does not negate the need for intensified screening\u003c\/strong\u003e in men with a positive family history. Family history remains an independent risk factor.\u003c\/p\u003e\n\n\u003cp\u003eExact definitions of risk groups and which PGVs to include still need to be established. Prospective trials have demonstrated the clinical utility of risk stratification based on baseline PSA with adjunct MRI in the general population. Growing evidence on PRS and risk calculators may further refine risk stratification. But while validation continues, men at high risk need recommendations \u003cstrong\u003enow\u003c\/strong\u003e, not after years of additional research.\u003c\/p\u003e\n\n\u003cp\u003eThe article presents two examples of risk-adapted screening protocols. The first comes from Germany's first dedicated clinic for early detection of prostate cancer in men with a family history of cancer or a PGV (trial NCT05681416). It relies on baseline PSA testing and \u003cstrong\u003emultiparametric MRI (mpMRI)\u003c\/strong\u003e for risk stratification, with the following structure for high-risk individuals aged 45 with no PGVs:\u003c\/p\u003e\n\n\u003ctable\u003e\n  \u003ctr\u003e\n    \u003cth\u003eRisk Group\u003c\/th\u003e\n    \u003cth\u003eRecommended Screening\u003c\/th\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\n\u003cstrong\u003eLow risk\u003c\/strong\u003e\u003cbr\u003e(PSA \u0026lt;3 ng\/ml and PI-RADS 1–2)\u003c\/td\u003e\n    \u003ctd\u003ePSA annually\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\n\u003cstrong\u003eIntermediate risk\u003c\/strong\u003e\u003cbr\u003e(PI-RADS 3 with ERSPC Risk Calculator 4 score \u0026lt;12%, or PSA ≥3 ng\/ml with PI-RADS 1–2)\u003c\/td\u003e\n    \u003ctd\u003ePSA annually; mpMRI after 1 year and then every 5 years, or earlier if PSA rises at a rate \u0026gt;0.7 ng\/ml\/year\u003c\/td\u003e\n  \u003c\/tr\u003e\n  \u003ctr\u003e\n    \u003ctd\u003e\n\u003cstrong\u003eHigh risk\u003c\/strong\u003e\u003cbr\u003e(PI-RADS 3 with ERSPC Risk Calculator 4 score \u0026gt;12%, or PI-RADS 4–5)\u003c\/td\u003e\n    \u003ctd\u003eMRI\/ultrasound fusion biopsy. If negative: PSA annually; mpMRI after 1 year and then every 5 years, or earlier if PSA rises at \u0026gt;0.7 ng\/ml\/year\u003c\/td\u003e\n  \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eFor men aged \u003cstrong\u003e40 with PGVs\u003c\/strong\u003e, the same protocol applies, but the screening starts five years earlier. The risk categories are based on PSA level (with \u003cstrong\u003e\u0026lt;3 ng\/ml\u003c\/strong\u003e considered low) and MRI findings using the \u003cstrong\u003ePI-RADS\u003c\/strong\u003e scoring system (with 1–2 considered low risk and 4–5 considered high risk), combined with the \u003cstrong\u003eERSPC Risk Calculator 4\u003c\/strong\u003e score (with a cutoff of \u003cstrong\u003e12%\u003c\/strong\u003e). A second US-based protocol (trial NCT06398639) similarly incorporates a polygenic risk score and relies on MRI and PSA to identify clinically relevant cancers requiring biopsy.\u003c\/p\u003e\n\n\u003cp\u003eThe authors also note that \u003cstrong\u003edigital rectal examination (DRE)\u003c\/strong\u003e performs poorly as a standalone screening tool and offers no added benefit when combined with PSA testing, based on recent evidence. The European Association of Urology has proposed a screening algorithm for the general population of men aged \u003cstrong\u003e50–70 years\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003eSeveral cross-cutting recommendations emerge for successful implementation:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAdequate counseling and shared decision-making\u003c\/strong\u003e about the pros and cons of PSA testing are essential for guideline compliance.\u003c\/li\u003e\n  \u003cli\u003ePolicies should ensure that intensified, risk-adapted screening for high-risk men is available \u003cstrong\u003ewithout additional out-of-pocket costs\u003c\/strong\u003e, to reduce disparities.\u003c\/li\u003e\n  \u003cli\u003eSpecialized, interdisciplinary centers (analogous to breast\/ovarian cancer centers) may facilitate the optimal implementation of risk stratification, screening, and counseling as an integrated workflow.\u003c\/li\u003e\n  \u003cli\u003eHowever, the \u003cstrong\u003efinancial sustainability\u003c\/strong\u003e of such comprehensive prevention centers is a central concern, and this model may not be feasible in many parts of the world. Cost-effectiveness research remains crucial to inform broader adoption in public health-care systems.\u003c\/li\u003e\n  \u003cli\u003eThe expansion of screening for high-risk men should align with structured, risk-adapted screening in the general population — beyond routine family history assessment, eligible men should receive \u003cstrong\u003einvitations to PSA testing\u003c\/strong\u003e, and testing should be performed only when indicated.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"conclusions\"\u003eConclusions: A Coordinated Call to Action\u003c\/h2\u003e\n\n\u003cp\u003eThe authors argue that even while research continues to investigate best-practice pathways, \u003cstrong\u003eimplementation of intensified screening for high-risk men is needed now\u003c\/strong\u003e. Genetic testing of index patients (the first person in a family identified with a mutation) and appropriate cascade testing should become more broadly available. This testing should use established criteria with validated tools and proceed with standardized referrals to genetic counseling where needed.\u003c\/p\u003e\n\n\u003cp\u003eProvider and patient education — together with dissemination of information about men's cancer risk and the importance of communicating genetic test results to male relatives — is crucial. Men identified as high risk should be offered risk-adapted prostate cancer screening, possibly through specialized interdisciplinary prostate cancer centers where available.\u003c\/p\u003e\n\n\u003cp\u003eFinally, the authors call for a \u003cstrong\u003ecoordinated agenda covering research, financing, and implementation\u003c\/strong\u003e to fill the evidence gaps for early detection of high-risk prostate cancer. This will require interdisciplinary collaboration among clinicians, researchers, health insurance companies, regulatory authorities, patient advocates, and industry — working together to align evidence generation, secure sustainable funding, and facilitate successful long-term implementation of early detection programs.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eWhat This Study Could Not Answer\u003c\/h2\u003e\n\n\u003cp\u003eThis is a \u003cstrong\u003ecall-to-action paper\u003c\/strong\u003e, not a clinical trial, so it has important limitations that patients should understand:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eThe proposed screening pathways are examples, with \u003cstrong\u003etrial validation pending\u003c\/strong\u003e (NCT05681416 in Germany and NCT06398639 in the USA).\u003c\/li\u003e\n  \u003cli\u003eThe optimal risk-stratified screening strategy remains under investigation, particularly with emerging imaging modalities and biomarker-based approaches.\u003c\/li\u003e\n  \u003cli\u003eCurrent genetic testing does not capture all relevant risk variants — earlier PRS models captured only \u003cstrong\u003e30–40% of familial relative risk\u003c\/strong\u003e.\u003c\/li\u003e\n  \u003cli\u003eThere is \u003cstrong\u003eno consensus\u003c\/strong\u003e on which precise PGVs should be included in intensive screening programs.\u003c\/li\u003e\n  \u003cli\u003eNon-White populations are under-represented in genetic research, limiting the applicability of current findings across ethnic groups.\u003c\/li\u003e\n  \u003cli\u003eThe psychosocial burden of genetic testing in high-risk men requires further study, since this population remains under-represented in such research.\u003c\/li\u003e\n  \u003cli\u003eThe \u003cstrong\u003ecost-effectiveness\u003c\/strong\u003e of specialized centers and risk-adapted screening programs remains uncertain, and this model may not be feasible in resource-limited settings.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch2 id=\"for-patients\"\u003eWhat This Means for You: Practical Steps\u003c\/h2\u003e\n\n\u003cp\u003eIf you are a man concerned about prostate cancer risk, this article provides several actionable takeaways. First, \u003cstrong\u003eknow your family history\u003c\/strong\u003e — and not just on your father's side. A family history of breast, ovarian, or colorectal cancer in any relative can also raise your prostate cancer risk.\u003c\/p\u003e\n\n\u003cp\u003eSecond, \u003cstrong\u003etalk to your doctor about genetic testing\u003c\/strong\u003e if you have a family history of prostate cancer, especially if a first-degree relative was diagnosed at a young age, or if you have metastatic prostate cancer yourself. The 37% of PGVs found in men with no family history mean family history alone is insufficient to guide testing decisions.\u003c\/p\u003e\n\n\u003cp\u003eThird, understand that \u003cstrong\u003eancestry matters\u003c\/strong\u003e. Men of African ancestry face a more than twofold higher genetic risk and should discuss earlier screening with their doctors. Men of Ashkenazi Jewish descent also have a higher prevalence of relevant genetic variants.\u003c\/p\u003e\n\n\u003cp\u003eFourth, if you are identified as high risk, expect a structured screening plan that likely includes \u003cstrong\u003eannual PSA testing and mpMRI\u003c\/strong\u003e, starting at age 40 if you carry a PGV or at age 45 if you have a strong family history. A rising PSA velocity (\u0026gt;0.7 ng\/ml\/year) should trigger earlier MRI. If you are at intermediate or high risk based on PSA and MRI findings, an MRI\/ultrasound fusion biopsy may be recommended.\u003c\/p\u003e\n\n\u003cp\u003eFinally, \u003cstrong\u003eparticipate in shared decision-making\u003c\/strong\u003e with your health-care team. Discuss the pros and cons of testing and screening, and if you carry a genetic variant, share that information with male relatives — it could save their lives too.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWho is at high risk for prostate cancer?\u003c\/h3\u003e\n\u003cp\u003eHigh risk includes men with a family history of prostate cancer, especially a father or brother diagnosed young, plus inherited mutations in genes like BRCA2, HOXB13, or Lynch syndrome genes. Men of African ancestry have a 2.18-fold higher genetic risk. A family history of breast, ovarian, or colorectal cancer also raises risk.\u003c\/p\u003e\n\u003ch3\u003eI have no family history of prostate cancer. Can I still carry a genetic mutation?\u003c\/h3\u003e\n\u003cp\u003eYes. In one large study, 37% of pathogenic germline variants occurred in men with no family history of prostate cancer. So relying only on family history would miss more than one-third of mutation carriers. Discuss genetic testing with your doctor if you have other risk factors or are concerned.\u003c\/p\u003e\n\u003ch3\u003eShould I get genetic testing for prostate cancer risk?\u003c\/h3\u003e\n\u003cp\u003eConsider testing if you have metastatic prostate cancer, a family history of prostate cancer (especially early-onset), or a family history of breast, ovarian, or colorectal cancer. Genetic testing can identify mutations in BRCA1\/2, HOXB13, and other genes. A negative result does not erase a strong family history—family history remains an independent risk factor.\u003c\/p\u003e\n\u003ch3\u003eHow does ancestry affect my prostate cancer risk?\u003c\/h3\u003e\n\u003cp\u003eMen of African ancestry have about a 2.18-fold higher genetic risk compared to European ancestry. Men of East Asian ancestry have a 0.73-fold lower risk. Germline variant prevalence is highest in Ashkenazi Jewish (22.7%) and White (17.8%) men, lower in African American (10.1%) and Hispanic (6.4%) men. Non-White populations are under-represented in research.\u003c\/p\u003e\n\u003ch3\u003eIf I am at high risk, what screening plan should I expect?\u003c\/h3\u003e\n\u003cp\u003eA structured plan may start at age 40 if you carry a pathogenic variant, or age 45 with strong family history. It typically includes annual PSA and mpMRI. Intermediate or high risk based on PSA, MRI, and risk calculator scores may lead to MRI\/ultrasound fusion biopsy. Rising PSA velocity over 0.7 ng\/ml\/year triggers earlier MRI.\u003c\/p\u003e\n\u003ch3\u003eCan genetic testing cause psychological distress?\u003c\/h3\u003e\n\u003cp\u003eThe IMPACT study of men with BRCA1\/2 mutations found low and largely stable distress over time, but a subgroup did report heightened distress. Genetic counseling should address individual situations and potential psychological burden. Psycho-oncological professionals may be the first contact for distressed patients but may need specific training in genetic testing issues.\u003c\/p\u003e\n\u003ch3\u003eWhat practical steps can I take to assess my prostate cancer risk?\u003c\/h3\u003e\n\u003cp\u003eKnow your full family history, including breast, ovarian, and colorectal cancer on both sides. Talk to your doctor about genetic testing if you have a family history or metastatic disease. Understand your ancestry's impact. If high risk, expect annual PSA and mpMRI starting at age 40–45. Share genetic results with male relatives—it could save lives.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Expanding Risk-adapted Early Detection of Prostate Cancer- A Call to Action for Men at High Risk\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Maike K. Klett, Peter Albers, Adam Kibel, Jale Lakes, Huma Q. Rana, Michael Serzan, André Karger, Alicia K. Morgans\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e European Urology Oncology, 2026 (DOI: 10.1016\/j.euo.2026.01.012)\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAffiliations:\u003c\/strong\u003e Heinrich-Heine-University Düsseldorf (Germany), Dana-Farber Cancer Institute \/ Harvard Medical School (Boston, USA), German Cancer Research Center (Heidelberg, Germany), Mass General Brigham \/ Harvard Medical School (Boston, USA)\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e This patient-friendly article is based on peer-reviewed research published as an open-access article under the CC BY license. It is intended for educational purposes and does not replace individualized medical advice. Always discuss your personal prostate cancer risk with a qualified healthcare professional.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47400025030812,"sku":null,"price":0.0,"currency_code":"KRW","in_stock":true}],"url":"https:\/\/diagnosticdetectives.kr\/products\/expanding-early-detection-of-prostate-cancer-what-men-at-high-risk-need-to-know","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}